Edwards target upped by Jefferies

Jefferies ups Edwards Lifesciences target to $155, says story ‘has legs’. After spending a day with management, Jefferies analyst Raj Denhoy raised his price target for Edwards Lifesciences to $155 from $150. The case was again made for why teens transcatheter valve growth is well supported over the short, medium and long term, Denhoy tells investors in a research note titled “Notes from the Road: The EW Story Has Legs.” The TAVR market is proving bigger than forecasts and Edwards’ position is secure, the analyst adds. He keeps a Buy rating on the shares.

https://bit.ly/2wjkddz